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ABSTRACT
Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor 
negative (ER–) breast cancer patients with bone metastasis. In the present 
bioinformatics study, we observed that LOX is a prognostic factor for poor progression 
free survival in patients with ER– breast cancer. LOX overexpression was positively 
correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively 
correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin 
and gemcitabine. LOX overexpression was also associated with EMT and stemness 
of cancer cells, which leads to chemotherapeutic resistance and poor outcome in 
ER– patients. Although we suggest several therapeutic interventions that may help 
in the management of LOX+ ER– breast cancer patients, experiments to validate the 
function of LOX in ER– breast cancer are still needed. 
INTRODUCTION
Breast cancers in which the tumor is estrogen 
receptor (ER)-negative (ER–) account for approximately 
30% of white patients [1] and about 40%–50% of Chinese 
patients [2]. These patients tend to have a poorer prognosis 
with a higher risk of disease recurrence and metastasis 
than patients with ER+ tumors. This is in part because 
there are fewer effective methods for preventing and 
treating ER– breast cancers. In addition, the molecular 
subtypes of ER– tumors are not well defined due to 
their biological heterogeneity. In recent years, however, 
a number of potential signaling pathways driving ER– 
breast cancer have been identified [3, 4]. This makes 
targeted therapy focusing on a specific molecular subtype 
a potentially effective strategy for managing ER– breast 
cancer patients. That said, the clinical application of such 
new approaches remains a prospect for the future. 
Lysyl oxidase (LOX) is an enzyme involved in 
regulating extracellular matrix (ECM) and connective 
tissue homeostasis [5]. Moreover, previous studies 
have shown that LOX plays a crucial role in mediating 
proliferation, migration, and invasion by endometrial 
and endometriotic cells. Specifically, LOX influences 
the expression of genes related to fibrosis and ECM 
remodeling, including E-cadherin [6], which is indicative 
of its pro-metastatic potential. A recent study by Thomas 
et al. [7] showed that LOX induces pre-metastatic bone 
lesions in breast cancer patients (especially ER– subgroup) 
by disrupting normal bone homeostasis. These lesions 
subsequently facilitate colonization by circulating tumor 
cells (CTCs), leading to bone metastasis. The authors 
of that report suggest administration of bisphosphonate 
to breast cancer patients with LOX overexpression may 
prevent establishment and proliferation of CTCs within 
bone. Nevertheless, the molecular mechanisms underlying 
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LOX-promoted ER–  breast cancer metastasis and the best 
approach to treating LOX+ ER– breast cancer patients 
remains unknown.
To promote translational research on LOX towards 
greater clinical significance, in this study, we address 
the following questions: how is LOX associated with 
metastasis and estrogen receptor 1 (ESR1) expression; 
why does bisphosphonate inhibit metastasis in patients 
overexpressing LOX; and are there any promising 
therapeutic options for managing LOX+ ER– breast 
cancer patients.
RESULTS
LOX overexpression is associated with poor PFS 
and metastasis
LOX overexpression is reported to be specifically 
associated with bone relapse in ER– breast cancer patients 
[7]. In the present study, we analyzed the Gyorffy dataset 
to explore the relation between LOX and progression free 
survival (PFS) in breast cancer patients. We found that 
LOX is associated with PFS among all patients (Figure 1A, 
P < 0.0001) and ER– patients (Figure 1B, P = 0.0009), but 
not ER+ patients (Figure 1C, P > 0.05). Furthermore, the 
results of gene set enrichment analysis (GSEA) indicate 
that LOX expression correlates positively with gene 
sets that represent cancer cell migration and metastasis 
in breast cancer (Figure 1D, P < 0.0001). GSEA also 
revealed that LOX expression correlates negatively with 
the ESR1 gene signature (Figure 2A, P = 0.008) and that 
LOX expression is significantly higher in ESR1-low than 
ESR1-high patients (Figure 2B). These results indicate 
that LOX is a strong predictor of poor PFS in ER– breast 
cancer patients and is closely associated with metastasis. 
Bisphosphonate is a therapeutic option for 
LOX+ breast cancer patients
Bisphosphonate treatment may suppress bone 
metastasis in ER– breast cancer patients overexpressing LOX 
[7]. To explore the underlying mechanism, we reanalyzed 
breast cancer data from The Cancer Genome Atlas, which 
revealed that LOX expression correlates with expression of 
matrix metallopeptidase 2 (MMP2) (Figure 3A, R2 = 0.47), 
collagen type I alpha1 (COL1A1) (Figure 3B, R2 = 0.47), 
and secreted protein acidic and rich in cysteine (SPARC) 
(Figure 3C, R2 = 0.51). Given that MMP2, COL1A1 and 
SPARC are all pro-metastatic genes [8–10], we suggest these 
genes play crucial roles in LOX+ breast cancer metastasis. 
In addition, data mining results from The Comparative 
Toxicogenomics Database indicates that bisphosphonate 
down-regulates expression of LOX, MMP2, COL1A1 and 
SPARC, which means bisphosphonate may suppress cancer 
metastasis by targeting these four genes.
Unfavorable characteristics correlated with LOX 
overexpression
We next sought to explore the mechanisms and 
characteristics underlying the LOX-associated poor 
PFS. GSEA results showed that LOX expression 
positively correlates with gene signatures that represent 
poor outcome after radiation therapy. This finding 
indicates that LOX+ breast cancer patients are resistant 
to radiation therapy (Figure 4A and 4B). Similarly, it 
may not be a good choice for LOX+ patients to choose 
doxorubicin (Figure 4C) or mitoxantrone (Figure 4D) 
for chemotherapy. Other analyses indicated that 
LOX overexpression correlates with epithelial-
mesenchymal transition (EMT) (Figure 4E and 4F) 
and activation of cancer stem cell pathways, such as 
the WNT and HEDGEHOG pathways (Figure 4G– 4I). 
Thus, resistance to radiation and certain drugs, 
EMT transition, and harboring cancer stem cell like 
characteristics may contribute to the LOX-related poor 
prognosis. 
Favorable characteristics correlated with LOX 
overexpression
Overexpression of LOX does present certain 
advantages. For instance, LOX expression correlates 
negatively with expression of genes associated with DNA 
repair (Figure 5A, P = 0.006), but correlates positively 
with genes down-regulated in samples resistant to 
cisplatin, trabectedin and gemcitabine (Figure 5B– 5D, 
P < 0.0001, P < 0.0001, P = 0.002, respectively). 
This indicates that cytotoxic drugs such as cisplatin 
and gemcitabine will likely achieve a better clinical 
response in patients overexpressing LOX. In addition, 
LOX expression is significantly higher among carriers 
of BRCA1 mutations than among those without BRCA1 
mutation (Figure 6A), though LOX expression does not 
differ between BRCA2 mutation and wild type carriers 
(Figure 6B). Since poly (ADP-ribose) polymerase 
(PARP) inhibitors are effective for treatment of breast 
cancer patients with BRCA1 mutation [11], this class 
of drugs may also be effective for managing breast 
cancer patients who overexpress LOX and carry BRCA1 
mutation.
Appropriate therapeutic options for LOX+ ER– 
breast cancer patients
Based on the analysis summarized above, the 
appropriate treatment options are illustrated in Figure 7. 
Briefly, radiation, doxorubicin and mitoxantrone would 
be ineffective in LOX+ ER– patients. On the other hand, 
a PARP1 inhibitor, cisplatin, trabectedin and gemcitabine 
may produce promising results.
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DISCUSSION
The ER– breast cancer subtype is associated with 
a significantly higher 5-year recurrence rate and fewer 
effective treatment strategies than is the ER+ subtype 
[12]. The outcomes of treatments aimed at suppressing 
key signaling pathways are far from satisfying due to 
the heterogeneity of ER– tumors [13]. At present, much 
effort is focused on the molecular subtyping of ER– breast 
cancers [3, 4]. For example, molecular markers such as 
mTOR and Src are reportedly involved in the development 
of ER– tumor metastasis [14].
Although strong evidence indicates LOX promotes 
bone metastasis in patients with breast cancer [7], the 
association between LOX and prognosis in ER– breast 
cancer patients remained unclear. We address that issue 
in the present study and show the significant prognostic 
power of LOX in ER– breast cancer. Given that survival 
us usually poor among patients with high LOX expression, 
LOX could be a useful biomarker to stratify patients with 
ER– breast cancer and direct personalized therapies.
Bisphosphonates are common medications used 
to treat osteoporosis and may suppress bone metastasis 
by inhibiting LOX [7], [15]. Moreover, our analysis 
Figure 1: LOX expression correlates with PFS and metastasis in breast cancer patients. LOX expression correlates negatively 
with the PFS among all breast cancer patients (A) and among ER– breast cancer patients (B). (C) There is no significant correlation between 
LOX expression and PFS among ER+ breast cancer patients. (D) GSEA analysis indicating that LOX expression correlates positively with 
migration and metastasis.
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Figure 2: LOX expression correlates negatively with ESR1 signatures (A) and ESR1 expression (B).
Figure 3: LOX expression correlates positively expression of MMP2 (A), COL1A1 (B) and SPARC (C). (D) Diagram 
summarizing results indicating bisphosphonate suppresses metastasis by inhibiting LOX, MMP2, COL1A1 and SPARC expression.
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Figure 4: LOX correlates positively with resistance to radiation therapy (A and B), doxorubicin (C) and mitoxantrone (D). 
LOX expression also correlates with mesenchymal gene expression signature (E) and TGF-β pathway activation (F). High levels of LOX 
expression correlates with overexpression of cancer stem cell markers (G) and activation of stem cell pathways such as the WNT (H) and 
HEDGEHOG (I) signaling pathways.
Figure 5: (A) LOX expression correlates negatively with DNA repair gene expression and with down-regulation of genes involved in 
cisplatin (B), trabectedin (C) and gemcitabine (D) resistance processes. 
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Figure 6: LOX expression is significantly higher in BRCA1 mutation carriers than the wild type group (A), whereas there is 
no difference between BRCA2 mutation carriers and the BRCA2 wild type group.
Figure 7: Appropriate therapeutic interventions for ER– LOX+ breast cancer patients.
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indicates that LOX is likely co-expressed with MMP2, 
COL1A1 and SPARC, all of which contribute to initiating 
cancer metastasis and EMT [9, 10, 16–18], and that 
bisphosphonates inhibit MMP2 activity [19, 20], COL1A1-
driven osteoporotic fracture [21] and SPARC-stimulated 
EMT [22, 23]. Bisphosphonates may also inhibit breast 
cancer progression by decreasing stromal TGF-β excretion 
and inhibiting TGF-β signaling in cancer cells [24]. Based 
on these findings, we suggest that bisphosphonates are 
potentially effective chemotherapeutics for treating LOX+ 
ER– breast cancer patients.
Gemcitabine and cisplatin are currently used in 
adjuvant settings for treatment of breast cancer. Hu 
et al. [25] showed cisplatin plus gemcitabine could be 
an alternative or even the preferred first-line therapeutic 
strategy for patients with metastatic triple-negative breast 
cancer. Since LOX expression positively correlates with 
cisplatin and gemcitabine sensitivity, LOX+ ER– breast 
cancer patients may show a higher response rate to these 
drugs.
Inhibition of PARP is an effective strategy for 
suppressing cancers with BRCA1 and BRCA2 mutations. 
There are currently several PARP inhibitors in clinical 
trials aimed at evaluating their efficacy for the management 
of BRCA-mutated breast cancers [11]. For instance, 
among patients with metastatic triple-negative breast 
cancer, the response rate was significantly higher among 
patients receiving chemotherapy plus iniparib (a PARP 
inhibitor) than among those receiving chemotherapy 
alone (56% vs. 34%, p = 0.01) [26]. It was also reported 
that preoperative combined gemcitabine, carboplatin and 
iniparib is effective for management of early-stage triple-
negative and BRCA1/2 mutation-associated breast cancer 
[27]. The correlation between LOX and BRCA mutation 
has never been reported before, but our analysis indicates 
that LOX expression correlates significantly with BRCA1 
mutation. Since BRCA1 mutation carriers are sensitive to 
PARP inhibitors, some LOX+ ER– breast cancer patients 
may also benefit from PARP inhibitors. 
In sum, our findings show that radiation, doxorubin 
and mitoxantrone will be less effective in patients 
overexpressing LOX, but that PARP inhibitors, cisplatin, 
trabectedin and gemcitabine may yield positive effects. A 
limitation of this study is that all the data presented are 
based on bioinformatics analyses. Still needed are wet lab 
experiments and well-designed clinical trials before any 
clinical significance can be attributed.
MATERIALS AND METHODS
Ethics statement
For this study, only publicly available datasets 
were downloaded and reanalyzed. The Research Ethics 
Committee of Zhejiang Provincial People’s Hospital 
therefore waived the requirement for ethical approval.
Genomic analysis
The Gyorffy dataset [28] (N = 3554) was used 
for survival analysis. Gene-Drug interaction data was 
downloaded from The Comparative Toxicogenomics 
Database [29] GSEA [30] and all other association analyses 
were performed using breast cancer data (level 3, N = 532) 
from The Cancer Genome Atlas (National Cancer Institute 
cancer genome atlas data portal. http://tcga-data.nci.nih.
gov/tcga/findArchives.htm. Accessed September 1, 2014).
Statistical analysis 
All the data were analyzed using standard statistical 
tests, including independent samples t-tests, log rank 
tests and Fisher’s exact tests. Values of P < 0.05 were 
considered significant. R 3.2.1 (R Foundation for 
Statistical Computing [http://www.r-project.org/]) and 
GraphPad Prism 5.01 (GraphPad Software, Inc. [www.
graphpad.com]) were utilized to perform the analyses.
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